Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Endocrinology

Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors

Christine Gicquel, Xavier Bertagna, Véronique Gaston, Joël Coste, Albert Louvel, Eric Baudin, Jérome Bertherat, Yves Chapuis, Jean-Marc Duclos, Martin Schlumberger, Pierre-François Plouin, Jean-Pierre Luton and Yves Le Bouc
Christine Gicquel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Bertagna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Véronique Gaston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joël Coste
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Louvel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Baudin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérome Bertherat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Chapuis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Duclos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schlumberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-François Plouin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Luton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Le Bouc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Genetic alterations, such as loss of heterozygosity (LOH) at the 17p13 and 11p15 loci and overexpression of the insulin-like growth factor (IGF)-II gene, are associated with the malignant phenotype in sporadic adrenocortical tumors. A high risk of recurrence after surgery for adrenocortical tumors is predicted in cases with regional invasion or distant metastases. However, patients with localized tumors also have a high risk of recurrence. Reliable prognostic markers are required to identify subjects at high risk of recurrence. The aim of this study was to assess the prognostic value of three molecular markers (17p13 LOH, 11p15 LOH, and overexpression of the IGF-II gene) by assessing disease-free survival in a large series of adult patients with sporadic adrenocortical tumors.

Adult patients (114) were prospectively followed up from diagnosis of the disease to June 1999 or to death. Malignancy was initially diagnosed in 18 patients (McFarlane stage III: n = 1 and stage IV: n = 17). The remaining 96 patients with localized adrenal disease at diagnosis (stage I: n = 60 and stage II: n = 36) were at risk of recurrence. Histological grade was assessed according to Weiss criteria, and tumors were classified into two groups (Weiss score ≤3 and Weiss score ≥4). Tumor samples were analyzed for LOH at the 17p13 and 11p15 loci and for IGF-II gene mRNA content.

17p13 LOH was a strong predictor of shorter disease-free survival in univariate analysis (P = 0.001; relative risk, 27), as were histological grade (Weiss score ≥4; P = 0.00001; relative risk, 15), 11p15 LOH (P = 0.004; relative risk, 9), tumor size (size >5 cm; P = 0.006; relative risk, 18), and overexpression of the IGF-II gene (P = 0.01; relative risk, 5). In a Cox proportional hazards regression model, histological grade (P = 0.04; relative risk, 4.2) and 17p13 LOH (P = 0.009; relative risk, 21.5) were independently associated with recurrence.

Molecular markers, particularly 17p13 LOH, are predictive of long-term outcome in patients with sporadic adrenocortical tumors. In patients who have undergone curative surgery, routine assessment of these tumor markers is a useful complement to histological scoring for predicting recurrence and guiding decisions for subsequent follow-up and management.

INTRODUCTION

ACC 3 is a tumor with an extremely poor prognosis, the survival rate being 20% at 5 years. Although the most common clinical presentation of patients with ACC is that of Cushing’s syndrome, with or without associated virilism, a high proportion of patients (30–40%) already have metastatic disease at the time of diagnosis (1 , 2) . The probability of long-term control is highest if surgery is performed at an early stage of the disease. However, it is very difficult to distinguish between benign and malignant tumors at this stage. A tumor is unequivocally malignant only if there is local and/or regional invasion, and/or distant metastases (McFarlane stages III and IV). In cases of purely localized disease (stages I and II), the pathological examination is often unable to provide an unambiguous answer and, in ∼30% of localized tumors, gives no indication at all. Estimation of the likelihood of malignancy is still based on ill-defined parameters, and there is a crucial need for reliable prognostic markers to assist clinicians in management decisions, which may include the administration of adjuvant chemotherapy after surgery.

Recent progress has shed some light on the biology of adrenocortical tumors. Clonal analysis and comparative genomic hybridization have provided evidence for a multistep process of tumorigenesis, with sequential progression from normal to adenomatous and eventually to malignant cells (3, 4, 5, 6) . It has been shown that discrete genetic markers are strongly associated with the malignant phenotype. Abnormalities in the imprinted 11p15 region (involving maternal 11p15 LOH with duplication of the active IGF-II paternal allele and resulting in strong overexpression of the IGF-II gene; Refs. 7, 8, 9 ), 17p13 LOH (10 , 11) , 2p16 LOH (6) , and 11q13 LOH (6 , 12, 13, 14) are all highly specific for malignant tumors.

This study evaluated the prognostic value of tumor molecular markers at the 11p15 and 17p13 loci in a single series of 96 patients prospectively followed-up after resection of a localized adrenocortical tumor. We show that, in comparison with classical pathological assessment, molecular markers have independent prognostic value with LOH at 17p13 giving the highest relative risk of recurrence. We propose that these molecular markers should be routinely evaluated for the management of adrenocortical tumors.

PATIENTS AND METHODS

Patients

Between 1987 and 1998, sporadic adrenocortical tumor (other than Conn’s adenoma) was diagnosed in 127 adult patients referred to our departments. We excluded 10 patients with malignant adrenocortical tumors referred for recurrence. Three patients (with stage I tumor) were lost to follow-up. The remaining 114 patients were followed until the date of their death, their last examination, or the end of the follow-up period (June 1999). For patients without recurrence, the minimal follow-up period was 12 months.

Clinical data and hormonal status were evaluated as described previously (15) . The stage of the tumor was assessed according to the McFarlane classification (16) . Pathological data were assessed according to Weiss criteria (17 , 18) ; for each patient, a Weiss score (0 to 9) was determined according to the presence or absence of the following nine histological features: high mitotic rate, atypical mitoses, high nuclear grade, low percentage of clear cells, necrosis, diffuse architecture of tumor, capsular invasion, sinusoidal invasion, and venous invasion.

Informed consent for analysis of leukocyte and tumor DNA and access to the collected information was obtained from all of the patients in accordance with national ethical rules.

This study was prospective, and the patients were managed in a uniform and centralized way within the framework of the Comete network.

For postoperative follow-up, patients were examined twice a year after operation for 2 years and annually thereafter. Hormonal evaluation, chest X-rays, and computerized tomography scans of the abdomen were carried out at each evaluation.

Methods

Tumor fragments obtained during surgery were immediately frozen in liquid nitrogen and stored at −80°C until DNA and RNA extraction. Control leukocyte DNA for reference was available for all of the patients.

DNA and RNA Preparation.

Nucleic acids were prepared from leukocytes and surgically removed adrenocortical tumors as described previously (8) .

17p13 Allelic Status.

17p13 allelic status was determined by Southern blotting using two different probes: the pYNZ22 probe (D17S5) mapping to 17p13.3 and recognizing a TaqI multiallelic polymorphism (19) and the pBHP53 genomic p53 probe (17p13.1) recognizing a BamHI biallelic polymorphism (20) . It was also assessed by PCR analysis with primers flanking an AccII polymorphism in the fourth exon of the human p53 gene (amino acid 72; Ref. 21 ). Genomic leukocyte and tumor DNA was amplified as described previously, digested with AccII, and subjected to electrophoresis in a 2% agarose gel.

11p15 Allelic Status.

11p15 allelic status was investigated by Southern blotting as described previously (9) .

To determine 17p13 and 11p15 allelic status, the restriction pattern of tumor DNA was compared in each case with that for leukocyte DNA.

IGF-II mRNA Tumor Content.

Tumor IGF-II mRNA content was evaluated by dot-blot analysis as described previously (9) and compared with normal control adrenal gland mRNA content. Normal control adrenal gland RNA was obtained from glands surgically removed during nephrectomy for kidney cancer.

Statistical Analysis

The primary study outcome was disease-free survival in patients with local disease at initial operation (McFarlane stages I and II). Disease-free survival was the time in months between initial operation and documented recurrence or to the end of the study (June 1999). Survival was censored if the patient did not exhibit recurrence or died from other causes.

Survival curves were constructed using the method of Kaplan-Meier and were compared and tested for statistical significance by log rank tests (univariate analysis).

Cox’s proportional hazards regression models were used to identify the factors independently predicting prognosis (multivariate analysis).

The χ2 and Mann-Whitney tests were used to compare groups for noncensored qualitative and quantitative variables, respectively.

The threshold for significance was P ≤ 0.05.

The calculations were performed using the SAS package (SAS Institute, Inc., Cary, NC).

RESULTS

Features at Presentation.

Patient characteristics are summarized in Table 1 ⇓ . The patients were 18–81 years old. The ratio of women:men was 3:2. The adrenal tumor was in the right adrenal gland in 66 patients and in the left in 48. Sixty-eight percent of the patients (n = 77) were referred for endocrine symptoms, and 86% (n = 98) exhibited an abnormal hormonal profile.

View this table:
  • View inline
  • View popup
Table 1

Features at presentation in 114 patients with sporadic adrenocortical tumors

Ninety-six patients had tumors restricted to the adrenal gland: 60 patients had tumors ≤5 cm in size (stage I), and 36 patients had tumors >5 cm in size (stage II). Eighteen patients had malignant tumors at diagnosis: 1 patient had a tumor confined to the adrenal gland with involvement of local lymph nodes (stage III), and 17 patients had stage IV tumors. Six patients had tumors invading adjacent organs (kidney, 1; veins, 5), and 11 patients had distant metastases. One hundred three patients (90%) underwent curative surgery.

All 18 of the patients with obviously malignant tumors had a Weiss score of 4 or more, and 82 (85%) patients with localized tumors had a Weiss score of 3 or less.

Molecular Abnormalities.

Most patients (98%) were informative for at least one 11p15 marker, and 78% patients were informative for at least one of the three 17p13 markers.

The frequencies of 17p13 LOH, 11p15 LOH, and overexpression of the IGF-II gene are shown in Table 1 ⇓ . Twenty-three of 34 tumors with 17p13 LOH displayed complete LOH and 11 displayed mosaicism. Thirty-five of 47 tumors with 11p15 LOH showed complete loss of one allele and duplication of the remaining allele and 12 showed mosaicism. Overexpression of the IGF-II gene resulted in very high IGF-II mRNA levels (10–1000 × those in normal adrenal tissue; Fig. 1 ⇓ ).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Southern-blot analysis of leukocyte DNA (L) and tumor DNA (T) from patients with adrenocortical tumors. DNA was digested with TaqI and hybridized with the pYNZ22 probe (17p13.1 locus; A) or the insulin probe (11p15.5 locus; B). Dot blot analysis of IGF-II gene expression in adrenocortical tumors compared with normal adrenal using human IGF-II cDNA as the probe (C). UPD, uniparental disomy.

Fig. 2 ⇓ shows the frequency of these three molecular defects (17p13 LOH, 11p15 LOH, and overexpression of the IGF-II gene) according to tumor stage (Fig. 2A) ⇓ and Weiss score (Fig. 2B) ⇓ . Molecular abnormalities were frequent in stage III and IV tumors, which were obviously malignant, and were also frequent in stage II tumors, occurring in 63–69% of tumors (Fig. 2A) ⇓ . According to pathology data (Fig. 2B) ⇓ , a high frequency of molecular abnormalities was already observed in tumors with a Weiss score of 2.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Incidence of molecular abnormalities according to tumor stage (A) or Weiss score (B). ▪, 17p13 LOH; Embedded Image, 11p15 LOH; ▧, overexpression of the IGF-II gene.

Disease-free Survival Analysis.

We carried out a prognostic study for the 96 patients diagnosed with localized adrenal disease. In this group, the median duration of follow-up was 44 months (range, 5 months-11.5 years). The Kaplan-Meier estimate of disease-free survival was 87% at 5 years (Fig. 3A) ⇓ . During the follow-up period, 4 patients died of unrelated cause: pancreatic cancer (1 case), amyloidosis (1 case), and stroke (2 cases).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Overall Kaplan-Meier disease-free survival in 96 patients with localized adrenocortical tumor at initial operation (A). Kaplan-Meier disease-free survival curves according to tumor size (B); histological grade (C); or comparing patients with tumors showing 17p13 LOH and normal heterozygous profiles (D); 11p15 LOH and normal heterozygous profiles (E); and high and normal IGF-II gene mRNA contents (F).

Eleven (12%) patients displayed recurrence 2–35 months after initial surgery (median = 10 months; Table 2 ⇓ ). Three had abdominal recurrence, and the others exhibited metastatic recurrence. Four of these patients had a Weiss score of 3. Only 1 of the 11 patients had no molecular abnormalities.

View this table:
  • View inline
  • View popup
Table 2

Initial characteristics and follow-up in patients with recurrence

In univariate analysis, disease-free survival was not linked to age or sex. The absence of secretion or the presence of a mixed secretion (most often glucocorticoid and androgen secretion) was associated with a poor prognosis [relative risk (95% CI), 3.4 (1–11.7) and 4.6 (1.35–15.9), respectively; Table 3 ⇓] . 17p13 LOH was found to be a strong predictor of shorter disease-free survival [relative risk (95% CI), 27.3 (3.5–213.6)] as were 11p15 LOH [relative risk (95% CI), 9.4 (2–43.5)] and overexpression of the IGF-II gene [relative risk (95% CI), 4.8 (1.4–16.5)]. Univariate analysis also showed both tumor size [≤5 cm versus >5; relative risk (95% CI), 17.9 (2.3–140)] and, particularly, histological grade [Weiss score ≤3 versus ≥4; relative risk (95% CI): 15.15 (4.4–52.1)] to be significant predictors of disease-free survival (Table 3) ⇓ .

View this table:
  • View inline
  • View popup
Table 3

Univariate analysis comparing disease-free survival for various prognostic factors (log rank tests)

The prognostic value of these factors is illustrated by Kaplan-Meier curves of disease-free survival (Fig. 3, B–F) ⇓ .

Multivariate analysis was carried out for 73 patients (patients informative for the three molecular markers). The predictive power of the three molecular markers (17p13 LOH, 11p15 LOH, and overexpression of the IGF-II gene) was compared with that of other clinical and biological factors. Proportional hazards regression analysis showed that 17p13 LOH was the only molecular marker that acted as an independent factor predictive of disease-free survival (P = 0.009; relative risk, 21.5). χ2 analysis also showed a strong correlation between 17p13 LOH and 11p15 LOH or overexpression of the IGF-II gene (P < 0.0001). Of the clinical and biological factors, older age (P = 0.04; relative risk, 1.06/year) and higher histological grade (P = 0.04; relative risk, 4.2) were also independent predictive factors (Table 4) ⇓ .

View this table:
  • View inline
  • View popup
Table 4

Multivariate analysis: proportional hazards regression, Cox model

DISCUSSION

One major problem in the management of adrenocortical tumors is distinguishing localized tumors with malignant behavior from those that are benign. No single parameter has been identified that detects malignancy with certainty, and the likelihood of malignancy is still estimated on ill-defined parameters (1 , 2) . The major limitation of prognostic studies is the rarity of ACCs. Only a few studies have been devoted to a comparison of benign and malignant adrenocortical tumors. Weiss et al. (17) assessed the value of nine histological criteria for analyzing the behavior of adrenocortical tumors and showed that tumors with four or more of these criteria almost always recurred or metastasized. However, this study was undertaken in a small series, consisting of only 43 patients. In a subsequent study, Weiss et al. (18) showed that a high mitotic rate was the only one of these pathological criteria associated with poor survival.

During the last decade, our understanding of the mechanisms of adrenal tumorigenesis has advanced, and a variety of genetic abnormalities have been described, most associated with the malignant phenotype. In particular, abnormalities of the 11p15 region and LOH at the 17p13 locus are highly specific to malignant adrenocortical tumors. We followed up, in a prospective study, a large series of patients managed in a uniform and centralized way. We determined 17p13 and 11p15 allelic status and IGF-II mRNA content in sporadic adrenocortical tumors from 114 patients. We found that these molecular abnormalities were frequent in tumors that were clearly malignant (stages III and IV), occurring in ∼85% of such tumors.

The final aim of the study was to evaluate the prognostic value of these markers in localized tumors, particularly tumors assigned a low grade on the basis of surgical (McFarlane) and pathological (Weiss) criteria. We confirmed that pathological variables such as tumor size and histological grade were strong predictors of recurrence. Indeed, most patients who relapsed had tumors >5 cm in diameter and a Weiss score of ≥4. Although powerful, the multifactorial analysis proposed by Weiss (17 , 18) may be difficult to apply to individual cases and requires trained pathologists. The score is not totally reliable and may differ from one area to another in the same tumor. Therefore, other diagnostic markers of malignancy are required. The three molecular markers tested were found to be strong predictors of disease-free survival in univariate analysis. The best predictor, strongly associated with a risk of relapse and with shorter disease-free survival, was 17p13 LOH. This was also the only molecular marker of independent prognostic significance in a multivariate analysis taking into account biological and pathological data.

This study has several limitations. Like Weiss score, these prognostic parameters are only available after surgery. However, it is possible to consider the use of this type of molecular evaluation for biopsy samples and for identifying tumors at risk of malignancy. Although this study is the largest available prospective study for a relatively rare disease, the frequency of events (recurrences in 11 cases) was low, and our results require confirmation in a larger series of patients.

The strong negative prognostic impact of 17p13 LOH suggests that the 17p13 locus probably includes specific target genes, the inactivation of which contributes to tumor progression. In this study, 17p13 allelic status was assessed at two loci: 17p13.3 (D17S5 marker) and 17p13.1 (p53 markers). Unlike other tumor models such as breast cancer (22 , 23) , in adrenocortical tumors, if reduction to homozygosity was detected with the 17p13.3 marker and patients were informative with one of the two p53 gene analysis systems, the 17p13 LOH also involved the p53 gene. However, p53 mutations (24, 25, 26, 27) 4 occur in only ∼25% of ACCs. This difference between p53 mutations and 17p13 LOH frequencies suggests that another tumor suppressor gene in this region is important for adrenal tumorigenesis. The allelic loss of 17p13 in adrenal tumors should now be investigated with a set of well-mapped markers to define accurately the smallest common region, which can then be used to test a number of recently cloned putative tumor suppressor genes such as the HIC-1, OVCA1, OVCA2, CRK, and ABR genes (28, 29, 30, 31) .

The other two molecular markers studied here concern the 11p15 region. This region is subject to parental imprinting. We characterized previously the 11p15 LOH as a parental isodisomy with loss of the maternal allele and duplication of the paternal allele (8 , 9) . This structural abnormality often leads to overexpression of the IGF-II gene, which is normally only expressed from the paternal allele (7, 8, 9) . Overexpression of the IGF-II gene is a common feature of various cancers (32 , 33) , and we have shown that this growth factor is involved in the proliferation of malignant adrenal H295R cells (34) . The greater prognostic value of 11p15 LOH than of overexpression of the IGF-II gene suggests that the loss of expression of genes normally expressed from the maternal allele is important in adrenal tumorigenesis. Indeed, most genes in the 11p15 region are maternally expressed and encode products with antiproliferative function. One of these products, p57KIP2, inhibits G1 cyclin-cyclin-dependent kinase complexes (35 , 36) . H19 could act as a tumor suppressor gene (37) , TSSC3 favors apoptosis (38) , and TSSC5, the function of which is still unknown, has been shown to be mutated in lung cancers (39) . Loss of H19 gene expression has been described in malignant adrenocortical tumors (9) . The p57KIP2 gene has also been evaluated in adrenal tumors and has been shown to be down-regulated in malignant tumors (40 , 41) , resulting in an increase in the kinase activity of G1 cyclin-cyclin-dependent kinase complexes (41) .

In conclusion, this prospective study establishes the prognostic value of molecular markers (particularly 17p13 allelic status) in the management of localized adrenocortical tumors. After complete resection of a localized tumor with molecular abnormalities, the patient should be followed in more detail, whatever the pathological evaluation. Whether adjuvant therapies such as mitotane or chemotherapy are of benefit and should be used in such patients remains to be tested in a prospective trial.

Acknowledgments

We thank Drs. F. Archambeaud, O. Chabre, R. Chadarevian, P. Chanson, P. Chedin, B. Delemer, F. Duron, M. Hautecourverture, I. Leroy, C. Mechelany, A. Pennfornis, M. L. Raffin-Sanson, E. Requeda, G. Schaison, P. Thomopoulos, P. Touraine, and J. Young for help in the assessment of patients.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Supported by Assistance Publique Hôpitaux de Paris, Contrat de Recherche Clinique Grant 97133; the University Paris VI, Faculté Saint-Antoine (Unité PRopre à l’Enseignement Supérieur EA 1531); Association de Recherche contre le Cancer (Grant 1364); Institut National de la Santé et de la Recherche Médicale (U515); and Projet Hospitalier de Recherche Clinique Grant AOM 95201 for the Comete Network.

  • ↵2 To whom requests for reprints should be addressed, at Laboratoire d’Explorations Fonctionnelles Endocriniennes, Hôpital Trousseau, 26 Avenue Arnold Netter, 75012 Paris, France. Phone: 33 1 44 73 64 47; Fax: 33 1 44 73 61 27; E-mail: christine.gicquel{at}trs.ap-hop-paris.fr

  • ↵3 The abbreviations used are: ACC, adrenocortical carcinoma; LOH, loss of heterozygosity; IGF, insulin-like growth factor; CI, confidence interval;

  • ↵4 Unpublished observations.

  • Received March 30, 2001.
  • Accepted July 16, 2001.
  • ©2001 American Association for Cancer Research.

References

  1. ↵
    Latronico A., Chrousos G. Extensive personal experience. Adrenocortical tumors. J. Clin. Endocrinol. Metab., 82: 1317-1324, 1997.
    OpenUrlCrossRefPubMed
  2. ↵
    Gicquel C., Le Bouc Y., Luton J. P., Bertagna X. Adrenocortical carcinoma: pathogenesis and treatment. Curr. Opin. Endocrinol., 5: 189-196, 1998.
  3. ↵
    Beuschlein F., Reincke M., Karl M., Travis W., Jaursch-Hancke C., Abdelhamid S., Chrousos G., Allolio B. Clonal composition of human adrenocortical neoplasms. Cancer Res., 54: 4927-4932, 1994.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Gicquel C., Leblond-Francillard M., Bertagna X., Louvel A., Chapuis Y., Luton J. P., Girard F., Le Bouc Y. Clonal analysis of human adrenocortical carcinomas and secreting-adenomas. Clin. Endocrinol., 40: 465-477, 1994.
    OpenUrlPubMed
  5. ↵
    Kjellman M., Kallioniemi O. P., Karhu R., Höög A., Farnebo L. O., Auer G., Larsson C., Backdahl M. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res., 56: 4219-4223, 1996.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Kjellman M., Roshani L., Teh B., Kallioniemi O. P., Höög A., Gray S., Farnebo L. O., Holst M., Karhu R., Bäckdahl M., Larsson C. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab., 84: 730-735, 1999.
    OpenUrlCrossRefPubMed
  7. ↵
    Ilvesmäki V., Kahri A., Miettinen P., Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab., 77: 852-858, 1993.
    OpenUrlCrossRefPubMed
  8. ↵
    Gicquel C., Bertagna X., Schneid H., Leblond-Francillard M., Luton J. P., Girard F., Le Bouc Y. Rearrangements at 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab., 78: 1444-1453, 1994.
    OpenUrlCrossRefPubMed
  9. ↵
    Gicquel C., Raffin-Sanson M., Gaston V., Bertagna X., Plouin P. F., Schlumberger M., Louvel A., Luton J. P., Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors. Study on a series of 82 tumors. J. Clin. Endocrinol. Metab., 82: 2559-2565, 1997.
    OpenUrlCrossRefPubMed
  10. ↵
    Yano T., Linehan M., Anglard P., Lerman M., Daniel L., Stein C., Robertson C., LaRocca R., Zbar B. Genetic changes in human adrenocortical carcinomas. J. Natl. Cancer Inst., 81: 518-523, 1989.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Gicquel C., Bertagna X., Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur. J. Endocrinol., 133: 133-144, 1995.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Heppner C., Reincke M., Agarwal S., Mora P., Allolio B., Burns A., Spiegel A., Marx S. MEN1 gene analysis in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab., 84: 216-219, 1999.
    OpenUrlCrossRefPubMed
  13. ↵
    Gortz B., Roth J., Speel E., Krahenmann A., De Krijger R., Matias-Guiu X., Muletta-Feurer S., Rutmann K., Saremaslani P., Heitz P., Komminoth P. MEN1 gene mutation analysis of sporadic adrenocortical lesions. Int. J. Cancer, 80: 373-379, 1999.
    OpenUrlCrossRefPubMed
  14. ↵
    Schulte K., Mengel M., Heinze M., Simon D., Scheuring S., Köhrer K., Röher H. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab., 85: 441-448, 2000.
    OpenUrlCrossRefPubMed
  15. ↵
    Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M., Louvel A., Chapuis Y., Blondeau P., Bonnin A., Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N. Engl. J. Med., 322: 1195-1201, 1990.
    OpenUrlPubMed
  16. ↵
    McFarlane D. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann. R. Coll. Surg. Engl., 23: 155-186, 1958.
    OpenUrlPubMed
  17. ↵
    Weiss L. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol., 8: 163-169, 1984.
    OpenUrlCrossRefPubMed
  18. ↵
    Weiss L., Medeiros J., Vickey A. Pathologic features of prognostic significance in adrenocortical carcinomas. Am. J. Surg. Pathol., 13: 202-206, 1989.
    OpenUrlCrossRefPubMed
  19. ↵
    Nakamura Y., Leppert M., O’Connell P., Wolff R., Holm T., Culver M., Martin C., Fujimoto E., Hoff M., Kumlin E., White R. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science (Wash. DC), 235: 1616-1622, 1987.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Hoyheim B., Nakamura Y., White R. A BamHI polymorphism is detected by a genomic p53-clone (pBHP53). Nucleic Acids Res., 17: 8898 1989.
    OpenUrlFREE Full Text
  21. ↵
    Ara S., Lee P., Hansen M., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18: 4961 1990.
    OpenUrlFREE Full Text
  22. ↵
    Merlo G., Venesio T., Bernardi A., Cropp C., Diella F., Cappa A., Callahan R., Liscia D. Evidence for a second tumor suppressor gene on chromosome 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet. Cytogenet., 76: 106-111, 1994.
    OpenUrlCrossRefPubMed
  23. ↵
    Liscia D., Morizio R., Venesio T., Palenzona C., Donadio M., Callahan R. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br. J. Cancer, 80: 821-826, 1999.
    OpenUrlCrossRefPubMed
  24. ↵
    Ohgaki H., Kleihues P., Heitz P. P53 mutations in sporadic adrenocortical tumors. Int. J. Cancer, 54: 408-410, 1993.
    OpenUrlPubMed
  25. ↵
    Lin S., Lee Y., Tsai J. Mutations of the p53 gene in human functional adrenal neoplasms. J. Clin. Endocrinol. Metab., 78: 483-491, 1994.
    OpenUrlCrossRefPubMed
  26. ↵
    Reincke M., Karl M., Travis W., Mastorakos G., Allolio B., Linehan H., Chrousos G. P53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab., 78: 790-794, 1994.
    OpenUrlCrossRefPubMed
  27. ↵
    Reincke M., Wachenfeld C., Mora P., Thumser A., Jaursch-Hancke C., Abdelhamid S., Chrousos G., Allolio B. P53 mutations in adrenal tumors: Caucasian patients do not show exon 4 “hot spot” found in Taiwan. J. Clin. Endocrinol. Metab., 81: 3636-3638, 1996.
    OpenUrlCrossRefPubMed
  28. ↵
    Morris C., Benjes S., Haataja L., Ledbetter D. H., Heisterkamp N., Groffen J. Spatial organization of ABR and CRK genes on human chromosome band 17p13.3. Oncogene, 10: 1009-1011, 1995.
    OpenUrlPubMed
  29. ↵
    Wales M. M., Biel M. A., el Deiry W., Nelkin B. D., Issa J. P., Cavenee W. K., Kuerbitz S. J., Baylin S. B. P53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med., 1: 570-577, 1995.
    OpenUrlCrossRefPubMed
  30. ↵
    Schultz D. C., Vanderveer L., Berman D. B., Hamilton T. C., Wong A. J., Godwin A. K. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res., 56: 1997-2002, 1996.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Hoff C., Seranski P., Mollenhauer J., Korn B., Detzel T., Reinhardt R., Ramser J., Poustka A. Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer. Genomics, 70: 26-33, 2000.
    OpenUrlCrossRefPubMed
  32. ↵
    Werner H., LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res., 68: 183-223, 1996.
    OpenUrlCrossRefPubMed
  33. ↵
    Khandwala H. M., McCutcheon I. E., Flyvbjerg A., Friend K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 21: 215-244, 2000.
    OpenUrlCrossRefPubMed
  34. ↵
    Logié A., Boulle N., Gaston V., Perin L., Boudou P., Le Bouc Y., Gicquel C. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol., 23: 23-32, 1999.
    OpenUrlAbstract
  35. ↵
    Mong-Hong L., Reynisdottir I., Massagué J. Cloning of p57KIP2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Matsuoka S., Edwards M., Bai C., Parker S., Zhang P., Baldini A., Harper J., Elledge S. P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Hao Y., Crenshaw T., Moulton T., Newcomb E., Tycko B. Tumour-suppressor activity of H19 RNA. Nature (Lond.), 365: 764-767, 1993.
    OpenUrlCrossRefPubMed
  38. ↵
    Lee M., Feinberg A. Genomic imprinting of a human apoptosis gene homologue, TSSC3. Cancer Res., 58: 1052-1056, 1998.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Lee M. P., Reeves C., Schmitt A., Su K., Connors T. D., Hu R. J., Brandenburg S., Lee M. J., Miller G., Feinberg A. P. Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5. Cancer Res., 58: 4155-4159, 1998.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Liu J., Kahri A. I., Heikkila P., Voutilainen R. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J. Clin. Endocrinol. Metab., 82: 1766-1771, 1997.
    OpenUrlCrossRefPubMed
  41. ↵
    Bourcigaux N., Gaston V., Logié A., Bertagna X., Le Bouc Y., Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab., 85: 322-330, 2000.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Research: 61 (18)
September 2001
Volume 61, Issue 18
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors
Christine Gicquel, Xavier Bertagna, Véronique Gaston, Joël Coste, Albert Louvel, Eric Baudin, Jérome Bertherat, Yves Chapuis, Jean-Marc Duclos, Martin Schlumberger, Pierre-François Plouin, Jean-Pierre Luton and Yves Le Bouc
Cancer Res September 15 2001 (61) (18) 6762-6767;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors
Christine Gicquel, Xavier Bertagna, Véronique Gaston, Joël Coste, Albert Louvel, Eric Baudin, Jérome Bertherat, Yves Chapuis, Jean-Marc Duclos, Martin Schlumberger, Pierre-François Plouin, Jean-Pierre Luton and Yves Le Bouc
Cancer Res September 15 2001 (61) (18) 6762-6767;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • PATIENTS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Abstract LB-131: Profile of glucose metabolism in bladder cancer patients and the inhibitory effect of sulforaphane on bladder cancer glycolysis by regulating microRNA expression
  • Abstract 6466: Serum immunoglobulins are an independent prognostic marker of time to first therapy in newly diagnosed chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL)
  • Abstract 6448: Oral cancer pain mediators released in exosomes are oncogenes with potential to shape the microenvironment and induce neuronal sensitivity
Show more Endocrinology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement